JP2014524479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524479A5 JP2014524479A5 JP2014527312A JP2014527312A JP2014524479A5 JP 2014524479 A5 JP2014524479 A5 JP 2014524479A5 JP 2014527312 A JP2014527312 A JP 2014527312A JP 2014527312 A JP2014527312 A JP 2014527312A JP 2014524479 A5 JP2014524479 A5 JP 2014524479A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- alkyl
- aryl
- membered
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- 125000003118 aryl group Chemical group 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 32
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 29
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 28
- 125000001188 haloalkyl group Chemical group 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 206010060862 Prostate cancer Diseases 0.000 claims description 18
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 18
- 210000002966 serum Anatomy 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 229940124530 sulfonamide Drugs 0.000 claims description 16
- 150000003456 sulfonamides Chemical class 0.000 claims description 16
- 238000009167 androgen deprivation therapy Methods 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 14
- 229960003604 testosterone Drugs 0.000 claims description 14
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 12
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 12
- 210000000988 bone and bone Anatomy 0.000 claims description 12
- 230000003247 decreasing effect Effects 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 230000001394 metastastic effect Effects 0.000 claims description 9
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000004982 dihaloalkyl group Chemical group 0.000 claims description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000004385 trihaloalkyl group Chemical group 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 229940127557 pharmaceutical product Drugs 0.000 claims description 7
- 208000010392 Bone Fractures Diseases 0.000 claims description 6
- 206010017076 Fracture Diseases 0.000 claims description 6
- 208000033830 Hot Flashes Diseases 0.000 claims description 6
- 206010060800 Hot flush Diseases 0.000 claims description 6
- 210000000577 adipose tissue Anatomy 0.000 claims description 6
- 201000000079 gynecomastia Diseases 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 5
- 102000006395 Globulins Human genes 0.000 claims description 2
- 108010044091 Globulins Proteins 0.000 claims description 2
- 239000003163 gonadal steroid hormone Substances 0.000 claims description 2
- 238000011474 orchiectomy Methods 0.000 claims description 2
- 239000003270 steroid hormone Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 32
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 40
- 239000003098 androgen Substances 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/215,679 | 2011-08-23 | ||
| US13/215,679 US9427418B2 (en) | 2009-02-23 | 2011-08-23 | Estrogen receptor ligands and methods of use thereof |
| PCT/US2012/052141 WO2013043304A1 (en) | 2009-02-23 | 2012-08-23 | Estrogen receptor ligands and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014524479A JP2014524479A (ja) | 2014-09-22 |
| JP2014524479A5 true JP2014524479A5 (enrdf_load_stackoverflow) | 2015-10-08 |
Family
ID=48444651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527312A Pending JP2014524479A (ja) | 2011-08-23 | 2012-08-23 | エストロゲン受容体リガンドおよびその使用方法 |
Country Status (10)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018342909B2 (en) * | 2017-09-27 | 2023-06-08 | Targimmune Therapeutics Ag | Castration resistant prostate cancer |
| CA3128331C (en) * | 2019-01-30 | 2024-06-18 | Margaret K. YU | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| WO2020157334A1 (en) * | 2019-02-01 | 2020-08-06 | Fondazione Per L'istituto Oncologico Di Ricerca (Ior) | Methods of treating castrate-resistant prostate cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158828B2 (en) * | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
| US8546451B2 (en) * | 2005-11-28 | 2013-10-01 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| EP2455362A1 (en) * | 2005-11-28 | 2012-05-23 | GTX, Inc. | Nuclear receptor binding agents |
| KR20130101146A (ko) * | 2009-02-23 | 2013-09-12 | 지티엑스, 인코포레이티드 | 에스트로겐 수용체 리간드 및 그 이용 방법 |
-
2012
- 2012-08-23 KR KR1020147007549A patent/KR20140064906A/ko not_active Withdrawn
- 2012-08-23 MX MX2014002105A patent/MX2014002105A/es unknown
- 2012-08-23 AU AU2012312902A patent/AU2012312902B2/en not_active Ceased
- 2012-08-23 CA CA2845890A patent/CA2845890A1/en not_active Abandoned
- 2012-08-23 RU RU2014111060/15A patent/RU2014111060A/ru not_active Application Discontinuation
- 2012-08-23 JP JP2014527312A patent/JP2014524479A/ja active Pending
- 2012-08-23 EP EP12834287.0A patent/EP2747562A4/en not_active Withdrawn
- 2012-08-23 CN CN201280051979.4A patent/CN103957706A/zh active Pending
- 2012-08-23 IN IN1959DEN2014 patent/IN2014DN01959A/en unknown
-
2014
- 2014-02-20 IL IL231070A patent/IL231070A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7146992B2 (ja) | 癌を治療するための方法 | |
| US9205086B2 (en) | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor | |
| JP2013501731A5 (enrdf_load_stackoverflow) | ||
| US20140051665A1 (en) | Prostate cancer therapy with hsp90 inhibitory compounds | |
| CN111285913B (zh) | 用于肿瘤治疗的11-脱氧皮质醇的17α,21-二酯 | |
| JP2014502641A5 (enrdf_load_stackoverflow) | ||
| EP2575810A1 (en) | Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor | |
| JP2014518848A (ja) | 糖尿病を治療するための選択的アンドロゲン受容体調節因子 | |
| EP2714039A1 (en) | Combination therapy of hsp90 inhibitory compounds with mek inhibitors | |
| JP2016506916A5 (enrdf_load_stackoverflow) | ||
| WO2012162584A1 (en) | Combination therapy of hsp90 inhibitory compounds with chk inhibitors | |
| JP2016040288A5 (enrdf_load_stackoverflow) | ||
| WO2012096919A1 (en) | Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors | |
| JP2019529581A5 (enrdf_load_stackoverflow) | ||
| RU2011137324A (ru) | Лиганды рецепторов эстрогенов и способы их применения | |
| IN2014DN05869A (enrdf_load_stackoverflow) | ||
| JP2014529584A5 (enrdf_load_stackoverflow) | ||
| JP2014524479A5 (enrdf_load_stackoverflow) | ||
| JP2016526049A5 (enrdf_load_stackoverflow) | ||
| JP2019516726A5 (enrdf_load_stackoverflow) | ||
| RU2014111060A (ru) | Лиганды рецептора эстрогена и способы их применения | |
| RU2006123939A (ru) | Лечение остеопороза, связанного с терапией ингибиторами ароматазы | |
| JP2017527627A (ja) | 喫煙者における非小細胞肺癌の治療のための、カルボプラチンおよびパクリタキセルと併用したベリパリブ | |
| US20170196853A1 (en) | Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer | |
| JP2015506988A5 (enrdf_load_stackoverflow) |